Lysosomal dysfunction plays an important role in neurodegenerative diseases, including Parkinson’s disease (PD) and possibly Parkinson-plus syndromes such as progressive supranuclear palsy (PSP). This role is exemplified by the involvement of variants in the GBA1 gene, which results in a deficiency of the lysosomal enzyme glucocerebrosidase and is the most frequently identified genetic factor underlying PD worldwide. Pathogenic variants in the SMPD1 gene are a recessive cause of Niemann–Pick disease types A and B. Here, we provide the first report on an association between a loss-of-function variant in the SMPD1 gene present in a heterozygous state (p.Pro332Arg/p.P332R, which is known to result in reduced lysosomal acid sphingomyelinase activity), with PSP-Richardson syndrome in three unrelated patients of Chinese ancestry.
Citations
Citations to this article as recorded by
The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy Piotr Alster, Natalia Madetko-Alster International Journal of Molecular Sciences.2025; 26(9): 3927. CrossRef
Parkinson’s Disease is Predominantly a Genetic Disease Shen-Yang Lim, Christine Klein Journal of Parkinson’s Disease.2024; 14(3): 467. CrossRef
Identification of Genetic Variants in Progressive Supranuclear Palsy in Southeast Asia Adeline Su Lyn Ng, Ai Huey Tan, Yi Jayne Tan, Jia Lun Lim, Michelle Mulan Lian, Alfand Marl Dy Closas, Azlina Ahmad‐Annuar, Shanthi Viswanathan, Yuen Kang Chia, Jia Nee Foo, Weng Khong Lim, Eng‐King Tan, Shen‐Yang Lim Movement Disorders.2024; 39(10): 1829. CrossRef
Genetic-based diagnostics of Parkinson’s disease and other Parkinsonian syndromes Emma N. Somerville, Ziv Gan-Or Expert Review of Molecular Diagnostics.2024; 24(12): 1111. CrossRef
Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression and promote the development of a preventive intervention for individuals at a higher risk of a worse disease prognosis. Moreover, the GBA1-regulated pathway provides new perspectives on the pathogenesis of PD, such as dysregulated sphingolipid metabolism, impaired protein quality control, and disrupted endoplasmic reticulum-Golgi trafficking. These perspectives have led to the development of novel disease-modifying therapies for PD targeting the GBA1-regulated pathway by repositioning treatment strategies for Gaucher’s disease. This review summarizes the current hypotheses on a mechanistic link between GBA1 variants and PD and possible therapeutic options for modulating GBA1-regulated pathways in PD patients.
Citations
Citations to this article as recorded by
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease Silvia Paola Caminiti, Micol Avenali, Alice Galli, Rachele Malito, Giada Cuconato, Caterina Galandra, Rosaria Calabrese, Andrea Pilotto, Alessandro Padovani, Fabio Blandini, Daniela Perani, Cristina Tassorelli, Enza Maria Valente npj Parkinson's Disease.2025;[Epub] CrossRef
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review Malco Rossi, Susen Schaake, Tatiana Usnich, Josephine Boehm, Nina Steffen, Nathalie Schell, Clara Krüger, Tuğçe Gül‐Demirkale, Natascha Bahr, Teresa Kleinz, Harutyun Madoev, Björn‐Hergen Laabs, Ziv Gan‐Or, Roy N. Alcalay, Katja Lohmann, Christine Klein Movement Disorders.2025; 40(4): 605. CrossRef
Challenges in Gaucher disease: Perspectives from an expert panel Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, S. Grace Prakalapakorn, Barry E. Rosenbloom, Dominick A. Tuason, Neal J. Weinreb Molecular Genetics and Metabolism.2025; 145(1): 109074. CrossRef
Acetal functionalized iminosugars for targeting β-glucocerebrosidase modulation Maria Giulia Davighi, Francesca Clemente, Camilla Matassini, Martina Cacciarini, Damiano Tanini, Andrea Goti, Amelia Morrone, Paolo Paoli, Francesca Cardona European Journal of Medicinal Chemistry.2025; 290: 117529. CrossRef
Comparative analysis of methods for measuring glucocerebrosidase enzyme activity in patients with Parkinson’s disease with the GBA1 variant Jin Hwangbo, Myung Jun Lee, Sang Jin Kim, Hyun Kyung Park, Jae-heyok Lee Frontiers in Neurology.2025;[Epub] CrossRef
A drug screening platform for protein expression levels in neurological disorders Farida Emran, Ibrahim Kays, Chiu-An Lo, Yueyang Li, Brian E. Chen BioTechniques.2025; : 1. CrossRef
Investigating plasma lipid profiles in association with Parkinson’s disease risk Houwen Zhang, Fangzheng Cao, Jialin Yu, Yu Liang, You Wu npj Parkinson's Disease.2025;[Epub] CrossRef
Efficient GBA1 editing via HDR with ssODNs by outcompeting pseudogene-mediated gene conversion upon CRISPR/Cas9 cleavage Joseph S. Lagas, Monica F. Sentmanat, Xiaoxia Cui Frontiers in Genome Editing.2025;[Epub] CrossRef
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease Makaila L. Furderer, Bahafta Berhe, Tiffany C. Chen, Stephen Wincovitch, Xuntian Jiang, Nahid Tayebi, Ellen Sidransky, Tae-Un Han International Journal of Molecular Sciences.2024; 25(3): 1827. CrossRef
Towards a Global View of Parkinson's Disease Genetics Marzieh Khani, Catalina Cerquera‐Cleves, Mariam Kekenadze, Peter Wild Crea, Andrew B. Singleton, Sara Bandres‐Ciga Annals of Neurology.2024; 95(5): 831. CrossRef
Exploring the Association between Cathepsin B and Parkinson’s Disease Changhao Lu, Xinyi Cai, Shilin Zhi, Xiaofen Wen, Jiaxin Shen, Tommaso Ercoli, Elena Rita Simula, Carla Masala, Leonardo A. Sechi, Paolo Solla Brain Sciences.2024; 14(5): 482. CrossRef
Microglia: roles and genetic risk in Parkinson’s disease Alex R. Trainor, Debra S. MacDonald, Jay Penney Frontiers in Neuroscience.2024;[Epub] CrossRef